Seeking Alpha·2025-11-18 17:24Core Insights - Zymeworks (ZYME) announced a strategic shift towards a royalty-driven growth model, leveraging its internal R&D capabilities and licensing agreements with major companies like Johnson & Johnson (JNJ) [1][3] Company Strategy - The company aims to enhance its revenue streams through a focus on royalties, which indicates a pivot from traditional revenue models to one that emphasizes partnerships and licensing [3] - This strategic move is supported by the company's internal research and development engine, suggesting a commitment to innovation and product development [3] Industry Context - The announcement comes in the context of a broader trend in the biotech industry where companies are increasingly seeking to establish licensing agreements to bolster financial stability and growth [3]